A Phase 2 interventional study of Fludarabine and Clofarabine in Graft Versus Host Disease, sponsored by Nantes University Hospital. Terminated at 1 site in France. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-07-15.
Sponsored by Nantes University Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Graft vs Host Disease with a site in France — 10 open to participants now, 14 under way, 4 of them phase 3. Graft vs Host Disease · France.
Among the 54 studies in Graft vs Host Disease with a site in France, this one is the 30th largest by enrollment of the 47 interventional ones that give a count, is one of 6 that started in 2018, is one of 16 in phase 2, and was the 30th registered.
804 studies on the registry are indexed under Graft vs Host Disease; 148 are open to participants now.
Browse Graft vs Host Disease studies →10 of the 54 studies in Graft vs Host Disease with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Bambino Gesù Hospital and Research Institute · Sites in France, Austria, Czechia and 6 more countries
Ages 3 mo–25 yrs
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Nantes University Hospital · Sites in France
Ages 18–70
Hospices Civils de Lyon · Sites in France
Ages 2+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 102 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 41 (40%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 22 · Phase 3 17 · Phase 4 3
First in 2002; this study’s year is marked. 6 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 47 is above the median of 35 across 639 interventional studies indexed under Graft vs Host Disease.
Median enrollment 65 across the 47 interventional studies, 30 across the 5 observational. Of the 34 that completed or were terminated, 13 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 54 have an industry lead sponsor. The 10 most frequent:
Nantes University Hospital is the lead sponsor of 839 studies on the registry; 191 are open to participants now.
Nantes University Hospital has 4 studies filed under Graft vs Host Disease — fewer than ten, so there is no comparison to draw.
4 of the studies in Graft vs Host Disease with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04629833Phase 3medac GmbHTreatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy | 2027-08 |
| NCT03229200Pharmacyclics Switzerland GmbHExtended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | 2027-05-10 |
| NCT07028112Assistance Publique - Hôpitaux de ParisImpact of Iron Overload on the Incidence of Liver Complications in Long-Term Survivors (≥10 Years) of Allogeneic Hematopoietic Stem-Cell Transplantation. | 2027-08-20 |
| NCT06252870Nantes University HospitalStudy Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation | 2027-10-18 |
Add all 4 to your calendar (.ics) → With an account.
Among the 54 studies in Graft vs Host Disease with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Acute or chronic graft versus host disease is still the major complication of stem cells transplantation regarding morbidity and mortality.
Recently, high dose cyclophosphamide utilization early after post-transplantation (day+ 3 and +4) not only for patients with HLA- haploidentical donor but also for patients with Human Leukocyte Antigen (HLA)-compatible donor, showed a great control of graft versus host disease after transplantation, allowing to consider stopping immunosuppressive treatment after the transplantation (Neoral=cyclosporine, cell-cept=mycophenolate mofetil). Indeed, this step has already been completed in myeloablative transplantation in adult patients.
This approach could enable to avoid in the end several complications related to long term immunosuppressive drugs administration, while promoting quicker immunity recovery.
The BALTIMORE conditioning regiment will be used in this study with peripheral stem cell transplantation and fludarabine will be replaced by clofarabine for myeloid diseases (Acute Myeloide Leukemia, Myelodysplasia , myelofibrosis, Chronic Myeoloid Leukemia..) because of better antitumoral activity in this setting.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
to allogenic transplantation, especially:
Contra-indications to cyclophosphamide:
Cardiac condition preventing high dose cyclophosphamide utilization :
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
patients with lymphoid hemopathy
Drug: Fludarabine · Radiation: Full body irradiation · Drug: Cyclophosphamide · Other: stem cell transplantation · Other: nuclear cells
patients with myeloid hemopathy
Drug: Clofarabine · Radiation: Full body irradiation · Drug: Cyclophosphamide · Other: stem cell transplantation · Other: nuclear cells
patients inclued after 14 dec 2020, received a conditionnement regimen with ATG on Day -2 to reduce GVHD GRADE 1-2 incidence
Drug: Fludarabine · Radiation: Full body irradiation · Drug: Cyclophosphamide · Other: stem cell transplantation · Other: nuclear cells · Drug: Thymoglobulin Injectable Product
patients inclued after 14 dec 2020, received a conditionnement regimen with ATG on Day -2 to reduce GVHD GRADE 1-2 incidence
Drug: Clofarabine · Radiation: Full body irradiation · Drug: Cyclophosphamide · Other: stem cell transplantation · Other: nuclear cells · Drug: Thymoglobulin Injectable Product
30 mg/m² Intravenous 5 days from Day-6 to Day-2
30 mg/m² Intravenous 5 days from Day-6 to Day-2
2 grays at Day-1
14 mg/kg intravenous 2 days at Day - 6 and day -5
50 mg/kg intravenous 2 days at day +3 and day +4
Also known as: hight dose
at D0 intraveinous Depending on donor : the stem cells will be extracted from blood (CD34+) or from bone marrow (CD34+ and nuclear cells)
Also known as: graft
CD3+ cells if needed after transplantation
Also known as: Donor Lymphocytes Injection (DLI)
At day -2 2.5 mg/kg for patients inclued after 14 dec 2020
Also known as: ATG
Incidence of grade 3 and 4 acute GVHD cortico-resistant
acute GVHD will be evaluated from International Mount Sinai criteria
Time frame: 100 days after transplantation
Engraftment
number of days in aplasia (neutrophils\< 0.5 Giga/L and platelets\<20 G/l, number of transfusions (red blood and platelets)
Time frame: one year
Engraftment
chimerism
Time frame: one year
disease free survival (DFS)
blood and bone marrow analysis
Time frame: one year, the last follow-up visit
Overall survival (OS)
clinical follow-up
Time frame: one year, the last follow-up visit
graft and relapse free survival
time between Day O and relapse
Time frame: one year
chronic GVHD
chronic GVHD will be assessed with NCI criteria for evaluation of chronic GVHD
Time frame: one year
non relapse mortality (NRM)
number of death unrelated to relapse or disease progression
Time frame: last follow-up visit
Chimerism
proportion of full and mixed donor chimerism
Time frame: 1, 2, 3, 6 and 12 months after transplantation
Immune reconstitution
lymphocytes, monocytes, T4, T8, Natural Killer (NK), B cells rates
Time frame: 3, 6 and 12 months after transplantation
Identification of ghost factors associated with GVHD
Statistical Models to Identify Subjects with Ghost Prognosis Factors Nguyen JM. 2015
Time frame: one year
Adverse events of grade 3 and 4 after transplantation
time of occurring and frequency of grade 3 and grade 4 adverse events (CTCAE criteria)
Time frame: one year
Infections frequency
time of occurring and frequency of viral (CytoMegalo Virus, Epstein Barr virus , BKV, adenovirus), bacterial, parasite and yeast infections, evaluated by Polymerase Chain Reaction (PCR), blood and urines cultures, biopsy if applicable
Time frame: one year
compare OS between patients with ATG and patients without ATG
OS
Time frame: one year, last follow-up visit
compare grade 2-4 and 3-4 acute GVHD between patients with ATG and patients without ATG
acute GVHD will be evaluated from International Mount Sinai criteria
Time frame: one year
compare chronic GVHD between patients with ATG and patients without ATG
chronic GVHD will be assessed with NCI criteria for evaluation of chronic GVHD
Time frame: one year
compare DFS between patients with ATG and patients without ATG
DFS
Time frame: one year, last follow-up visit
compare Relapse between patients with ATG and patients without ATG
Relapse
Time frame: one year, last follow-up visit
compare NRM between patients with ATG and patients without ATG
NRM
Time frame: one year, last follow-up visit
compare Infections frequency between patients with ATG and patients without ATG
time of occurring and frequency of viral (CytoMegalo Virus, Epstein Barr virus , BKV, adenovirus), bacterial, parasite and yeast infections, evaluated by Polymerase Chain Reaction (PCR), blood and urines cultures, biopsy if applicable
Time frame: one year
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2018 to primary completion in Oct 2021, 45 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.